Untreated CNS metastatic disease, leptomeningeal disease, or cord compression
Known leptomeningeal carcinomatosis, uncontrolled/unstable spinal cord compression, or brain metastases.
History of leptomeningeal disease or spinal cord compression secondary to metastasis
Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids (participants receiving anticonvulsants are eligible).
Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
No concurrent leptomeningeal disease or cord compression
Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
Symptomatic brain metastases, leptomeningeal carcinomatosis, or spinal cord compression (treated metastatic brain, leptomeningeal carcinomatosis, or spinal cord compression are allowed); Note: Patients must be off steroids used for brain metastases, leptomeningeal carcinomatosis, or spinal cord compression
Leptomeningeal carcinomatosis or cord compression
In the dose-finding portion of the study, participants with known or suspected parenchymal brain, spinal cord, leptomeningeal disease prior to study enrollment will be excluded; in the dose-expansion portion of the study, known or suspected parenchymal brain or spinal cord disease, and/or suspected or symptomatic leptomeningeal disease prior to study enrollment will be excluded; asymptomatic leptomeningeal disease only will be allowed in the dose-expansion cohort
Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment.
PHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nPatients with evidence of CNS metastasis, spinal cord compression, or leptomeningeal disease within one year prior to enrollment will be excluded from this clinical trial; patients with a remote history of brain metastases may be considered if they received sterilizing therapy to the CNS (resection or radiation) and have been CNS progression free for the 1-year period; baseline imaging to rule out brain metastases is not required for screening, but should be performed prior to study enrollment if clinically indicated; patients with spinal cord compression may be considered if the condition is medically managed and currently asymptomatic
PHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients with evidence of CNS metastasis, spinal cord compression, or leptomeningeal disease within six months prior to enrollment will be excluded from this clinical trial; patients with a remote history of brain metastases may be considered if they received sterilizing therapy to the CNS (resection or radiation) and have been CNS progression free for the six months period; baseline imaging to rule out brain metastases is not required for screening, but should be performed prior to study enrollment if clinically indicated; patients with spinal cord compression may be considered if the condition is medically managed and currently asymptomatic
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients with evidence of CNS metastasis, spinal cord compression, or leptomeningeal disease within 1 year prior to enrollment will be excluded from this clinical trial; patients with a remote history of brain metastases may be considered if they received sterilizing therapy to the CNS (resection or radiation) and have been CNS progression-free for the 1-year period; baseline imaging to rule out brain metastases is not required for screening, but should be performed prior to study enrollment if clinically indicated; patients with spinal cord compression may be considered if the condition is medically managed and currently asymptomatic
Have symptomatic leptomeningeal carcinomatosis or spinal cord compression. Patients with asymptomatic leptomeningeal disease and no evidence of spinal cord compression are allowed.
Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
Known or suspected brain metastasis or active leptomeningeal disease or spinal cord compression
Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression; patients with any of these not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
Patient must not have known symptomatic leptomeningeal or brain metastases or spinal cord compression
History of central nervous system (CNS) lymphoma, leptomeningeal disease or spinal cord compression.
Presence of, or history of, central nervous system (CNS) lymphoma, leptomeningeal disease or spinal cord compression.
Patients with known leptomeningeal or brain metastases or spinal cord compression should be excluded from this clinical trial
Have current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Patients with leptomeningeal disease and without cord compression are allowed.
have previously documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression
Has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.
Have documented brain metastases, leptomeningeal disease or uncontrolled spinal cord compression.
Spinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain metastases
The participant has documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.
Patients with history of brain metastases, spinal cord compression, or a history of leptomeningeal carcinomatosis;
Patients with history of brain metastases, spinal cord compression, or leptomeningeal carcinomatosis
Current leptomeningeal metastases or spinal cord compression due to disease.
Evidence of ongoing spinal cord compression or leptomeningeal carcinomatosis
Leptomeningeal metastases or spinal cord compression due to disease.
Have symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
Brain metastases, or spinal cord compression. Individuals with brain metastases are allowed if they have been treated with irradiation or surgery, are clinically stable without steroid treatment. Individuals with documented leptomeningeal disease are not eligible.
Symptomatic leptomeningeal, brain metastases, or spinal cord compression.
Known leptomeningeal involvement, brain metastases or spinal cord compression.
History of leptomeningeal disease or spinal cord compression secondary to metastasis.
Subjects with leptomeningeal or brain metastases or spinal cord compression.
Has brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease
Previous brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.
Subjects must not have a history of clinically manifested central nervous system (CNS) metastases. a. Subjects with known or suspected leptomeningeal disease or cord compression are not eligible.
History of leptomeningeal disease or spinal cord compression
Known or suspected brain metastasis or active leptomeningeal disease or spinal cord compression